SAN DIEGO — Santarus, Inc. (NASDAQ:SNTS), a specialty pharmaceutical company, today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for a new tablet formulation to add to its ZEGERIDŽ family of branded prescription pharmaceutical products. The new formulation is an immediate-release tablet that combines omeprazole, a proton pump inhibitor (PPI), with a mix of buffers. The company’s objective is to have the new ZEGERID tablet product commercially available in the U.S. in the fourth quarter of 2009.

Read the full article: http://www.centredaily.com/business/technology/story/1090187.html